Table 1.
Clinical Characteristics of the Study Population
| Glucose Below 140 mg/dL, n = 2252 | Glucose Above 140 mg/dL, n = 135 | P Value | |
|---|---|---|---|
| Age, y (range) | 65 ± 13 (24–95) | 67 ± 13 (31–91) | 0.08 |
| Males | 1613 (72%) | 92 (68%) | 0.44 |
| BMI | 27 ± 4.5 | 27 ± 4.2 | 0.85 |
| Diabetes | 273 (12%) | 49 (36%) | <0.001 |
| Current smokers | 568 (25%) | 30 (22%) | 0.44 |
| Hypertension | 1402 (62%) | 91 (67%) | 0.23 |
| Dyslipidemia | 1483 (66%) | 88 (65%) | 0.874 |
| Ischemic heart disease | 1008 (45%) | 60 (44%) | 0.94 |
| Prior stroke | 229 (10%) | 16 (12%) | 0.53 |
| Prior CABG | 300 (13%) | 15 (11%) | 0.46 |
| Indications for coronary angiography | |||
| MI | 798 (35%) | 86 (64%) | <0.001 |
| Unstable angina | 609 (27%) | 22 (16%) | |
| Stable angina | 845 (38%) | 27 (20%) | |
| Medications | |||
| ACE inhibitors | 983 (44%) | 48 (36%) | 0.07 |
| Aspirin | 1865 (83%) | 110 (82%) | 0.69 |
| β‐blockers | 1362 (61%) | 57 (42%) | <0.001 |
| Clopidogrel | 898 (40%) | 53 (39%) | 0.89 |
| Angiotensin receptor blockers | 184 (8%) | 11 8%) | 0.99 |
| Statins | 1545 (69%) | 66 (49%) | <0.001 |
| Oral hypoglycemics | 147 (6.5%) | 33 (24%) | <0.001 |
| Insulin | 14 (1%) | 7 (5%) | <0.001 |
| Laboratory | |||
| High‐sensitivity C‐reactive protein | 10 ± 24 | 12 ± 27 | 0.84 |
| Total cholesterol | 168 ± 39 | 172 ± 36 | 0.24 |
| Triglycerides | 131 ± 81 | 111 ± 63 | <0.001 |
| Low‐density lipoprotein | 100 ± 33 | 107 ± 34 | 0.01 |
| High‐density lipoprotein | 42 ± 12 | 43 ± 12 | 0.4 |
| Hemoglobin A1c | 5.7 ± 0.4 | 5.9 ± 0.4 | <0.001 |
| Troponin, pg/dL | 2.5 ± 8.7 (0.01‐0.69) | 2.3 ± 7.5 (0.03‐0.95) | 0.87 |
| Coronary artery disease severity | |||
| 0 vessel | 541 (24%) | 18 (10%) | 0.001 |
| 1 vessel | 490 (22%) | 35 (26%) | |
| 2 vessel | 537 (24%) | 29 (22%) | |
| 3 vessel/LM | 674 (30%) | 53 (39%) |
Abbreviations: ACE, angiotensin‐converting enzyme; BMI, body mass index; CABG, coronary artery bypass graft; LM, left main; MI, myocardial infarction.